Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

809
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
809
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

697
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
697
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

751
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
751
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

800
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
800
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

849
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
849
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

634
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
634

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MAX-SHOCK: A Pragmatic Randomized Controlled Trial Comparing Biphasic Defibrillators Used in Routine Cardioversion of Atrial Fibrillation.

CJC open·2026
Same author

The First 50 Years of the University of Ottawa Heart Institute: Toward Heart Health for All.

The Canadian journal of cardiology·2026
Same author

Left atrial myopathy development and progression in atrial fibrillation patients with recurrent left atrial ablation procedures: the LAMP-AF study.

Heart rhythm·2026
Same author

Comparing the prognostic utility of late gadolinium enhancement burden and phenotype in patients with cardiac sarcoidosis; a prospective cohort study.

European heart journal. Imaging methods and practice·2026
Same author

Markers of left atrial cardiopathy and cognitive function trajectories in adults aged ≥ 45 years without atrial fibrillation: a population-based study.

BMC neurology·2026
Same author

High incidence of pacing-induced cardiomyopathy in patients with cardiac sarcoidosis.

Heart rhythm·2026
Same journal

Pneumonia Reimagined: Host, Microbe, and the Shifting Landscape of Disease.

Clinics in chest medicine·2026
Same journal

Advocacy in Pneumonia.

Clinics in chest medicine·2026
Same journal

Vaccines Against Pneumonia: Current Updates.

Clinics in chest medicine·2026
Same journal

Non-antibiotic Treatments for Pneumonia: Host-Directed Therapies, Next-Steps and Future Directions.

Clinics in chest medicine·2026
Same journal

Customizing Antibiotic Treatment for Pneumonia: Can We Have a Single Unified Algorithm for All Types of Pneumonia?

Clinics in chest medicine·2026
Same journal

The Role of Complex Digital Interventions to Improve Pneumonia Care.

Clinics in chest medicine·2026
See all related articles

Related Experiment Video

Updated: Mar 29, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

10.7K

Cardiac Sarcoidosis.

David Birnie1, Andrew C T Ha2, Lorne J Gula3

  • 1Division of Cardiology, University of Ottawa Heart Institute, 40 Ruskin Street, Ottawa, Ontario K1Y 4 W7, Canada.

Clinics in Chest Medicine
|November 24, 2015
PubMed
Summary
This summary is machine-generated.

Cardiac involvement in sarcoidosis affects 5% of patients, with 20-25% having silent heart issues. Screening is recommended, with immunosuppression and device therapy for manifest cardiac sarcoidosis.

Keywords:
Atrioventricular blockCardiac sarcoidosisClinically manifestClinically silentHeart failureSudden cardiac deathVentricular arrhythmias

More Related Videos

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

8.1K
Generation of Murine Cardiac Pacemaker Cell Aggregates Based on ES-Cell-Programming in Combination with Myh6-Promoter-Selection
08:52

Generation of Murine Cardiac Pacemaker Cell Aggregates Based on ES-Cell-Programming in Combination with Myh6-Promoter-Selection

Published on: February 17, 2015

10.2K

Related Experiment Videos

Last Updated: Mar 29, 2026

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes
11:00

Assessment of Sarcoplasmic Reticulum Calcium Reserve and Intracellular Diastolic Calcium Removal in Isolated Ventricular Cardiomyocytes

Published on: September 18, 2017

10.7K
Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

8.1K
Generation of Murine Cardiac Pacemaker Cell Aggregates Based on ES-Cell-Programming in Combination with Myh6-Promoter-Selection
08:52

Generation of Murine Cardiac Pacemaker Cell Aggregates Based on ES-Cell-Programming in Combination with Myh6-Promoter-Selection

Published on: February 17, 2015

10.2K

Area of Science:

  • Cardiology
  • Pulmonology
  • Immunology

Background:

  • Sarcoidosis commonly affects the lungs but can involve the heart.
  • Clinically manifest cardiac sarcoidosis (CS) presents with conduction abnormalities, arrhythmias, and heart failure.
  • Asymptomatic cardiac involvement is found in 20-25% of systemic sarcoidosis patients.

Purpose of the Study:

  • To review the diagnosis and management of cardiac sarcoidosis.
  • To highlight the prevalence and prognosis of clinically silent cardiac involvement.
  • To discuss current treatment recommendations for CS.

Main Methods:

  • Literature review of studies on cardiac sarcoidosis.
  • Analysis of clinical manifestations and diagnostic criteria for CS.
  • Evaluation of treatment guidelines for CS.

Main Results:

  • Clinically manifest cardiac involvement occurs in approximately 5% of sarcoidosis patients.
  • Asymptomatic cardiac involvement is significantly more prevalent, affecting 20-25% of patients.
  • Prognosis for clinically silent CS is generally benign, while manifest CS requires intervention.

Conclusions:

  • Screening for cardiac involvement is recommended for all patients with pulmonary/systemic sarcoidosis.
  • Immunosuppression is indicated for clinically manifest CS.
  • Device therapy, such as implantable cardioverter-defibrillators, is recommended for select CS patients.